Have a feature idea you'd love to see implemented?
Let us know!
SRPT Sarepta Therapeutics Inc
Price (delayed)
$110.5
Market cap
$10.55B
P/E Ratio
70.83
Dividend/share
N/A
EPS
$1.56
Enterprise value
$11.75B
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going
Highlights
The net income has soared by 158% QoQ and by 118% YoY
The EPS has soared by 120% YoY and by 108% from the previous quarter
Sarepta Therapeutics's quick ratio has decreased by 49% YoY and by 12% from the previous quarter
Sarepta Therapeutics's gross margin has decreased by 2.7% from the previous quarter
Key stats
What are the main financial stats of SRPT
Market
Valuations
Earnings
Shares outstanding
95.52M
Market cap
$10.55B
Enterprise value
$11.75B
Price to earnings (P/E)
70.83
Price to book (P/B)
8.63
Price to sales (P/S)
6.43
EV/EBIT
90.84
EV/EBITDA
63.82
EV/Sales
7.17
Revenue
$1.64B
EBIT
$129.4M
EBITDA
$184.19M
Free cash flow
-$470.4M
Per share
Balance sheet
Liquidity
EPS
$1.56
Free cash flow per share
-$4.93
Book value per share
$12.8
Revenue per share
$17.2
TBVPS
$37.74
Total assets
$3.6B
Total liabilities
$2.38B
Debt
$1.4B
Equity
$1.22B
Working capital
$1.99B
Debt to equity
1.14
Current ratio
3.84
Quick ratio
2.33
Net debt/EBITDA
6.51
Margins
Efficiency
Dividend
EBITDA margin
11.2%
Gross margin
85.9%
Net margin
7.4%
Operating margin
4.9%
Return on assets
3.6%
Return on equity
11.8%
Return on invested capital
3.5%
Return on capital employed
4.5%
Return on sales
7.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SRPT stock price
How has the Sarepta Therapeutics stock price performed over time
Intraday
-0.32%
1 week
1.27%
1 month
-13.2%
1 year
31.42%
YTD
14.59%
QTD
-11.52%
Financial performance
How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$1.64B
Gross profit
$1.41B
Operating income
$81.03M
Net income
$121.85M
Gross margin
85.9%
Net margin
7.4%
The net income has soared by 158% QoQ and by 118% YoY
SRPT's net margin has surged by 139% since the previous quarter and by 112% year-on-year
SRPT's operating income has soared by 120% year-on-year and by 113% since the previous quarter
SRPT's operating margin has soared by 114% YoY and by 96% from the previous quarter
Growth
What is Sarepta Therapeutics's growth rate over time
Valuation
What is Sarepta Therapeutics stock price valuation
P/E
70.83
P/B
8.63
P/S
6.43
EV/EBIT
90.84
EV/EBITDA
63.82
EV/Sales
7.17
The EPS has soared by 120% YoY and by 108% from the previous quarter
The company's equity has surged by 60% YoY and by 13% QoQ
SRPT's P/B is 36% below its 5-year quarterly average of 13.5 and 26% below its last 4 quarters average of 11.7
The P/S is 52% less than the 5-year quarterly average of 13.3 and 23% less than the last 4 quarters average of 8.3
The revenue rose by 48% YoY and by 9% QoQ
Efficiency
How efficient is Sarepta Therapeutics business performance
The ROA has soared by 140% from the previous quarter and by 116% YoY
The return on equity has surged by 127% since the previous quarter and by 111% year-on-year
Sarepta Therapeutics's ROIC has soared by 117% YoY and by 106% from the previous quarter
The ROS has soared by 113% YoY and by 93% from the previous quarter
Dividends
What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SRPT.
Financial health
How did Sarepta Therapeutics financials performed over time
The total assets is 51% more than the total liabilities
Sarepta Therapeutics's quick ratio has decreased by 49% YoY and by 12% from the previous quarter
The company's current ratio fell by 29% YoY
SRPT's debt is 14% greater than its equity
The company's equity has surged by 60% YoY and by 13% QoQ
The debt to equity has declined by 36% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.